Regeneron Pharmaceuticals has announced positive Phase 2 results for two investigational monoclonal antibodies, REGN7508 and REGN9933, which target different domains of Factor XI to control thrombosis ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback